Ibex Medical Analytics, a leader in AI-powered cancer diagnostics, has announced the launch and rollout of Galen 3.0 – a transformative solution offering new detection capabilities and a broad set of features to support pathologists in the diagnosis of multiple tissue types across various digital pathology workflows. Galen 3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.
Creating a new modality for cancer diagnosis, Galen is one of the first and most widely deployed AI technology in pathology and used in routine clinical practice at laboratories, hospitals and health systems worldwide.
Galen supports pathologists across numerous diagnostic tasks during the review of breast, prostate and gastric biopsies and helps improve the quality of cancer diagnosis, reduce turnaround time, boost productivity and improve user experience for pathologists. Galen demonstrated outstanding outcomes across clinical studies performed in multiple pathology labs and diagnostic workflows 1, 2, 3, 4, 5.
Galen 3.0 incorporates the very latest evolution of Ibex’s AI algorithms for detecting cancer and other clinically relevant features in prostate, breast and gastric biopsies.
To ensure very high accuracy and generalizability, Ibex trained the Deep Learning networks on huge, enriched data sets from laboratories worldwide that were digitised by multiple scanning systems, including rare prostatic malignancies such as intraductal carcinoma, neuroendocrine tumour, colorectal adenocarcinoma, lymphoma and urothelial carcinoma.
Galen also calculates a Gleason score, tumour size and percentage for each cancer slide, potentially enabling pathologists to save review time and reduce subjectivity.